ID
32578
Description
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma
Mots-clés
Versions (2)
- 07/11/2018 07/11/2018 -
- 07/12/2018 07/12/2018 -
Détendeur de droits
GSK group of companies
Téléchargé le
7 novembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837
Patient's Diary Card 1: Screening/Run-In Visit 1
- StudyEvent: ODM
Description
Daily Assessments
Description
Date
Type de données
text
Description
0 = No symptoms during the day or previous night 1 = Symptoms for one short period during the day or previous night 2 = Symptoms for two or more short periods during the day or previous night 3 = Symptoms for most of the day or previous night which did not affect my normal activities 4 = Symptoms for most of the day or previous night which did affect my normal activities 5 = Symptoms so severe that I could not go to work or perform normal activities Circle only one number
Type de données
text
Description
if nono, enter zero (0)
Type de données
integer
Similar models
Patient's Diary Card 1: Screening/Run-In Visit 1
- StudyEvent: ODM
Aucun commentaire